The NPC1L1 Gene Exerts a Notable Impact on the Reduction of Low-Density Lipoprotein Cholesterol in Response to Hyzetimibe: A Factorial-Designed Clinical Trial

Background: Hyzetimibe is a novel inhibitor of cholesterol that specifically targets the NPC1L1 gene. Significant inter-individual variability suggests the existence of an abundance of poor responders and non-responders. In addition, the current literature is inconsistent and controversial regarding...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Jianwei, Yang, Liyun, Zhou, Luping, Zhao, Hongbin, Qi, Xiao, Cui, Yimin, Ouyang, Dongsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963242/
https://www.ncbi.nlm.nih.gov/pubmed/35359877
http://dx.doi.org/10.3389/fphar.2022.755469

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963242/
https://www.ncbi.nlm.nih.gov/pubmed/35359877
http://dx.doi.org/10.3389/fphar.2022.755469

Ejemplares similares